top of page
Blue Shapes

Pioneering Breakthrough Therapeutics & Empowering
Hope for Improved Patient
Outcomes

Patients are our priority, designing curative medicines is our mission

Our primary focus is patients suffering from currently incurable life altering diseases. The disruptive PRISM™ Platform is a leading-edge novel physics-based drug design engine that has resulted in a pipeline of clinic-ready assets for the treatment of diseases across multiple clinical areas including neurology, oncology, and infectious disease.

News & Press Releases

Therapeutic Focus Areas

NEUROLOGY

~3B

people living with neurological disease

POST-INFECTION

NEUROPATHOLOGY

100M

people affected by post-infection illness

85%

DRUG-INDUCED

NEUROPATHY

of chemo patients have dose-limiting neurotoxicity

1 in 6

INFECTIOUS DISEASES

deaths worldwide caused by infectious disease

Solving the most challenging diseases  

Explore Asha's leading disease indications and the science behind our medicines

image.png

Amyotrophic Lateral Sclerosis

The Problem

ALS, also known as Lou Gehrig's disease, is a fatal neurodegenerative disorder characterized by the progressive loss of motor function. Nerve cells that control muscle function are lost in ALS patients. 

Asha's Solution

SARM1 is a key regulator of nerve cell degeneration in ALS. Asha has developed a novel intramolecular glue inhibitor of SARM1 that is restoring motor function in preclinical models of ALS.

ASHA-624

IND-enabling

Intra-molecular Glue - SARM1 Inhibitor

bottom of page